Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Artificial interferons for treatment of infections

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20200519003
Publicado:
25/05/2020
Caducidad:
26/05/2021
Resumen:
A German university offers chimeric mutants of interferon alpha 2 and other interferon alpha subtypes with improved antiviral activity for treatment of chronic or acute viral infections, bacterial or parasitic infections or tumour therapy. These interferons are characterized by a high biocompatibility. The university offers license agreements.

Details

Tittle:
Artificial interferons for treatment of infections
Summary:
A German university offers chimeric mutants of interferon alpha 2 and other interferon alpha subtypes with improved antiviral activity for treatment of chronic or acute viral infections, bacterial or parasitic infections or tumour therapy. These interferons are characterized by a high biocompatibility. The university offers license agreements
Description:
Interferons are a family of proteins that were originally named for their ability to interfere with viral replication and propagation. To date, it is known that interferons are also involved in combating bacterial and parasitic infections, inhibit cell division, and promote or impede the differentiation of cells. Of the known IFN alpha (IFNa) subtypes, only IFNa2 has been extensively studied for its pharmaceutical potential. IFNa2 is therapeutically used for treatment of chronic infection with Hepatitis B Virus (HBV), but leads to a sustained virus control in less than 20% of the treated patients. In chronic human immunodeficiency Virus (HIV) infection its efficacy is even lower, with the results that it has been clinically used in only very few studies.

Researchers of a German university have discovered that IFNa14 is more efficient for the treatment of HBV and HIV infections. Whereas the most potent IFNa subtype against influenza virus is IFNa16. These findings were not only generated in vitro, but also in humanized mouse models and human organoid cultures. Based on these and earlier findings regarding the different antiviral activities of IFNa subtypes, the researchers designed chimeric mutants of the known IFNa2 and IFNa6/IFNa14/IFNa16 proteins that use the IFNa2 backbone, which is clinically well-established, with a variety of point mutations derived from the IFNa6/IFNa14/IFNa16 amino acid sequences that show significantly higher antiviral activity than IFNa2 (see figure).

Several mutants have been generated for the treatment of chronic (e.g. HBV, HDV, HIV) or acute (e.g. Influenza, Zika, Corona) viral infections, bacterial or parasitic infections or for adjunct tumor therapy (e.g. renal-cell carcinomas, cutaneous melanoma, hairy-cell leukemia, leukemia, melanomas).

The university offers license agreements to pharmaceutical industry.
Advantages and Innovations:
· Higher antiviral efficacy than conventional IFN alpha 2 therapy
· High biocompatibility
· IFNa2 as drug backbone is clinically well-established
· Applies to a broad range of viruses
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
A European priority application has been filed

Partner sought

Type and Role of Partner Sought:
The invention is available for licensing and further development together with the researchers of the university. Potential partners come from the pharmaceutical industry.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001003 Citología, cancerología, oncología
06001015 Productos farmacéuticos / medicamentos
06001018 Virus, virología / antibióticos / bacteriología